An Open Label, Multicenter Study to Assess the Safety and Efficacy of Leuprorelin in the Treatment of Central Precocious Puberty
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 19 Apr 2017
At a glance
- Drugs Leuprorelin (Primary)
- Indications Precocious puberty
- Focus Adverse reactions
- Sponsors Takeda
- 11 Apr 2017 Planned End Date changed from 1 Mar 2018 to 31 Dec 2018.
- 11 Apr 2017 Planned primary completion date changed from 1 Mar 2018 to 31 Dec 2018.
- 11 Apr 2017 Status changed from recruiting to active, no longer recruiting.